Barry Hardy (Douglas Connect), Frank Hollinger (Sphaera Pharma) and Michael Liebman (Strategic Medicine)
Michael Liebman (Strategic Medicine)
Charles Commons, Johns Hopkins University
10 East 33rd Street
Baltimore, MD, USA 21218
chaired by Michael Liebman (Strategic Medicine)
The discussions in this session will help flush out the real problems and issues involved in current practices in translational medicine, identify the strengths and weaknesses in the approaches being used and explore new strategies that might be of use to address and achieve improved translational success.
This session will discuss:
|-||integrating heterogenous evidence supporting decision making|
|-||interdisciplinary challenges to transfer of evidence|
|-||limitations in current "big data" approaches in medical research|
|-||disease targeting and portfolio prioritization|
|-||hypothesis generation in clinical trial development|
|-||polypharmacy in the elderly: reality in hypertension and diabetes|
|-||understanding complexity supporting judgements|
|-||practices to get to better clinical decisions|
Practitioners will share guidance and tools based on their experiences with the attendees within a community of practice approach.
We will additionally discuss emerging translational practices and business opportunities which participants may join forces on. The InnovationWell Colaboration Pool supports the profiling and joining together of matching partners to respond to emerging opportunties.